Neumann M, Adler S, Schluter O, et al. Alpha-synuclein accumulation in a case of neurodegeneration with brain iron accumulation type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome) with widespread cortical and brainstem-type Lewy bodies. Acta Neuropathol (Berl). 2000 Nov. 100(5):568-74. [Medline].
Szumowski J, Bas E, Gaarder K, Schwarz E, Erdogmus D, Hayflick S. Measurement of brain iron distribution in Hallevorden-Spatz syndrome. J Magn Reson Imaging. 2010 Feb. 31(2):482-9. [Medline].
Schneider SA, Hardy J, Bhatia K. Iron Accumulation in Syndromes of Neurodegeneration with Brain Iron Accumulation 1 and 2 - causative or consequential?. J Neurol Neurosurg Psychiatry. 2009 Jan 15. [Medline].
Jankovic J, Kirkpatrick JB, Blomquist KA, et al. Late-onset Hallervorden-Spatz disease presenting as familial parkinsonism. Neurology. 1985 Feb. 35(2):227-34. [Medline].
Grimes DA, Lang AE, Bergeron C. Late adult onset chorea with typical pathology of Hallervorden-Spatz syndrome. J Neurol Neurosurg Psychiatry. 2000 Sep. 69(3):392-5. [Medline].
Cooper GE, Rizzo M, Jones RD. Adult-onset Hallervorden-Spatz syndrome presenting as cortical dementia. Alzheimer Dis Assoc Disord. 2000 Apr-Jun. 14(2):120-6. [Medline].
Saito Y, Kawai M, Inoue K, et al. Widespread expression of alpha-synuclein and tau immunoreactivity in Hallervorden-Spatz syndrome with protracted clinical course. J Neurol Sci. 2000 Aug 1. 177(1):48-59. [Medline].
Hickman SJ, Ward NS, Surtees RA, et al. How broad is the phenotype of Hallervorden-Spatz disease?. Acta Neurol Scand. 2001 Mar. 103(3):201-3. [Medline].
Taylor TD, Litt M, Kramer P, et al. Homozygosity mapping of Hallervorden-Spatz syndrome to chromosome 20p12.3-p13. Nat Genet. 1996 Dec. 14(4):479-81. [Medline].
Zhou B, Westaway SK, Levinson B, et al. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden- Spatz syndrome. Nat Genet. 2001 Aug. 28(4):345-9. [Medline].
Hogarth P. Neurodegeneration with brain iron accumulation: diagnosis and management. J Mov Disord. 2015 Jan. 8 (1):1-13. [Medline].
Perry TL, Norman MG, Yong VW, Whiting S, Crichton JU, Hansen S, et al. Hallervorden-Spatz disease: cysteine accumulation and cysteine dioxygenase deficiency in the globus pallidus. Ann Neurol. 1985 Oct. 18 (4):482-9. [Medline].
Hayflick SJ. First scientific workshop on Hallervorden-Spatz syndrome: executive summary. Pediatr Neurol. 2001 Aug. 25 (2):99-101. [Medline].
Gregory A, Polster BJ, Hayflick SJ. Clinical and genetic delineation of neurodegeneration with brain iron accumulation. J Med Genet. 2009 Feb. 46 (2):73-80. [Medline].
Johnson MA, Kuo YM, Westaway SK, Parker SM, Ching KH, Gitschier J, et al. Mitochondrial localization of human PANK2 and hypotheses of secondary iron accumulation in pantothenate kinase-associated neurodegeneration. Ann N Y Acad Sci. 2004 Mar. 1012:282-98. [Medline].
Kotzbauer PT, Truax AC, Trojanowski JQ, Lee VM. Altered neuronal mitochondrial coenzyme A synthesis in neurodegeneration with brain iron accumulation caused by abnormal processing, stability, and catalytic activity of mutant pantothenate kinase 2. J Neurosci. 2005 Jan 19. 25 (3):689-98. [Medline].
Leoni V, Strittmatter L, Zorzi G, Zibordi F, Dusi S, Garavaglia B, et al. Metabolic consequences of mitochondrial coenzyme A deficiency in patients with PANK2 mutations. Mol Genet Metab. 2012 Mar. 105 (3):463-71. [Medline].
Hayflick SJ. Defective pantothenate metabolism and neurodegeneration. Biochem Soc Trans. 2014 Aug. 42 (4):1063-8. [Medline].
Swaiman KF. Hallervorden-Spatz syndrome. Pediatr Neurol. 2001 Aug. 25 (2):102-8. [Medline].
Halliday W. The nosology of Hallervorden-spatz disease. J Neurol Sci. 1995 Dec. 134 Suppl:84-91. [Medline].
Rodriguez-Raecke R, Roa-Sanchez P, Speckter H, Fermin-Delgado R, Perez-Then E, Oviedo J, et al. Grey matter alterations in patients with Pantothenate Kinase-Associated Neurodegeneration (PKAN). Parkinsonism Relat Disord. 2014 Sep. 20 (9):975-9. [Medline].
Gregory A, Hayflick SJ. Pantothenate Kinase-Associated Neurodegeneration. GeneReviews. Jan 2013.
Vakili S, Drew AL, Von Schuching S, Becker D, Zeman W. Hallervorden-Spatz syndrome. Arch Neurol. 1977 Dec. 34 (12):729-38. [Medline].
Zimmerman AW, Stover ML, Grasso JA. Uptake of 59Fe by skin fibroblasts and MAO activity in platelets from patients with Hallervorden-Spatz syndrome. Neurology. 1981. 51:48.
Swaiman KF, Smith SA, Trock GL, Siddiqui AR. Sea-blue histiocytes, lymphocytic cytosomes, movement disorder and 59Fe-uptake in basal ganglia: Hallervorden-Spatz disease or ceroid storage disease with abnormal isotope scan?. Neurology. 1983 Mar. 33 (3):301-5. [Medline].
Alberca R, Rafel E, Chinchon I, Vadillo J, Navarro A. Late onset parkinsonian syndrome in Hallervorden-Spatz disease. J Neurol Neurosurg Psychiatry. 1987 Dec. 50 (12):1665-8. [Medline].
Hermann W, Reuter M, Barthel H, Dietrich J, Georgi P, Wagner A. Diagnosis of Hallervorden-Spatz disease using MRI, (123)I-beta-CIT-SPECT and (123)I-IBZM-SPECT. Eur Neurol. 2000. 43 (3):187-8. [Medline].
Kang A, Minoshima S. 123I-ioflupane SPECT findings of pantothenate kinase-associated neurodegeneration. Clin Nucl Med. 2014 Sep. 39 (9):849-51. [Medline].
Feliciani M, Curatolo P. Early clinical and imaging (high-field MRI) diagnosis of Hallervorden-Spatz disease. Neuroradiology. 1994 Apr. 36 (3):247-8. [Medline].
Lee JH, Gregory A, Hogarth P, Rogers C, Hayflick SJ. Looking Deep into the Eye-of-the-Tiger in Pantothenate Kinase-Associated Neurodegeneration. AJNR Am J Neuroradiol. 2018 Jan 25. [Medline].
McNeill A, Birchall D, Hayflick SJ, Gregory A, Schenk JF, Zimmerman EA, et al. T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation. Neurology. 2008 Apr 29. 70 (18):1614-9. [Medline].
Sethi KD, Adams RJ, Loring DW, el Gammal T. Hallervorden-Spatz syndrome: clinical and magnetic resonance imaging correlations. Ann Neurol. 1988 Nov. 24 (5):692-4. [Medline].
Delgado RF, Sanchez PR, Speckter H, Then EP, Jimenez R, Oviedo J, et al. Missense PANK2 mutation without "eye of the tiger" sign: MR findings in a large group of patients with pantothenate kinase-associated neurodegeneration (PKAN). J Magn Reson Imaging. 2012 Apr. 35 (4):788-94. [Medline].
Chiapparini L, Savoiardo M, D'Arrigo S, Reale C, Zorzi G, Zibordi F, et al. The "eye-of-the-tiger" sign may be absent in the early stages of classic pantothenate kinase associated neurodegeneration. Neuropediatrics. 2011 Aug. 42 (4):159-62. [Medline].
Dusek P, Bahn E, Litwin T, Jabłonka-Salach K, Łuciuk A, Huelnhagen T, et al. Brain iron accumulation in Wilson disease: a post mortem 7 Tesla MRI - histopathological study. Neuropathol Appl Neurobiol. 2017 Oct. 43 (6):514-532. [Medline].
Stoeter P, Roa-Sanchez P, Speckter H, Perez-Then E, Foerster B, Vilchez C, et al. Changes of cerebral white matter in patients suffering from Pantothenate Kinase-Associated Neurodegeneration (PKAN): A diffusion tensor imaging (DTI) study. Parkinsonism Relat Disord. 2015 Jun. 21 (6):577-81. [Medline].
Hartig MB, Hörtnagel K, Garavaglia B, Zorzi G, Kmiec T, Klopstock T, et al. Genotypic and phenotypic spectrum of PANK2 mutations in patients with neurodegeneration with brain iron accumulation. Ann Neurol. 2006 Feb. 59 (2):248-56. [Medline].
Lin CI, Chen KL, Kuan TS, Lin SH, Lin WP, Lin YC. Botulinum toxin injection to improve functional independence and to alleviate parenting stress in a child with advanced pantothenate kinase-associated neurodegeneration: A case report and literature review. Medicine (Baltimore). 2018 May. 97 (20):e10709. [Medline].
Liu Z, Liu Y, Yang Y, Wang L, Dou W, Guo J, et al. Subthalamic Nuclei Stimulation in Patients With Pantothenate Kinase-Associated Neurodegeneration (PKAN). Neuromodulation. 2017 Jul. 20 (5):484-491. [Medline].
Orellana DI, Santambrogio P, Rubio A, Yekhlef L, Cancellieri C, Dusi S, et al. Coenzyme A corrects pathological defects in human neurons of PANK2-associated neurodegeneration. EMBO Mol Med. 2016 Oct. 8 (10):1197-1211. [Medline].
Rohani M, Razmeh S, Shahidi GA, Alizadeh E, Orooji M. A pilot trial of deferiprone in pantothenate kinase-associated neurodegeneration patients. Neurol Int. 2017 Dec 11. 9 (4):7279. [Medline].
Christou YP, Tanteles GA, Kkolou E, Ormiston A, Konstantopoulos K, Beconi M, et al. Open-Label Fosmetpantotenate, a Phosphopantothenate Replacement Therapy in a Single Patient with Atypical PKAN. Case Rep Neurol Med. 2017. 2017:3247034. [Medline].
Justesen CR, Penn RD, Kroin JS, Egel RT. Stereotactic pallidotomy in a child with Hallervorden-Spatz disease. Case report. J Neurosurg. 1999 Mar. 90 (3):551-4. [Medline].
Mikati MA, Yehya A, Darwish H, Karam P, Comair Y. Deep brain stimulation as a mode of treatment of early onset pantothenate kinase-associated neurodegeneration. Eur J Paediatr Neurol. 2009 Jan. 13 (1):61-4. [Medline].
Castelnau P, Cif L, Valente EM, Vayssiere N, Hemm S, Gannau A, et al. Pallidal stimulation improves pantothenate kinase-associated neurodegeneration. Ann Neurol. 2005 May. 57 (5):738-41. [Medline].
Hogarth P, Kurian MA, Gregory A, Csányi B, Zagustin T, Kmiec T, et al. Consensus clinical management guideline for pantothenate kinase-associated neurodegeneration (PKAN). Mol Genet Metab. 2017 Mar. 120 (3):278-287. [Medline].
Santana M, Alvarez F, Baez A, Roa-Sanchez P, Stoeter P. Neurologic improvement after a hypercaloric diet in two patients with pantothenate kinase-associated neurodegeneration. The Journal of Rare Disorders. 2015. 3:45.